These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33538412)

  • 41. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer.
    Ikeda J; Ohe C; Yoshida T; Kuroda N; Saito R; Kinoshita H; Tsuta K; Matsuda T
    Pathol Int; 2021 Mar; 71(3):173-182. PubMed ID: 33503295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Lee A; Lee HJ; Huang HH; Ho H; Chen K
    Int J Urol; 2019 Apr; 26(4):481-486. PubMed ID: 30834632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
    Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
    Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
    Shimizu F; Muto S; Taguri M; Ieda T; Tsujimura A; Sakamoto Y; Fujita K; Okegawa T; Yamaguchi R; Horie S
    Int J Urol; 2017 May; 24(5):367-372. PubMed ID: 28281310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. B7‑H3 promotes malignant progression of muscle‑invasive bladder cancer.
    Xu ZL; Zhang Y; Wang L; Li F; Man HW; Li PF; Shan BE
    Oncol Rep; 2018 Nov; 40(5):2722-2733. PubMed ID: 30132557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular and immunohistochemical evaluation of BAP-1 antibody in bladder cancer and comparison with luminal-basal subtyping.
    Gürbüz BÇ; Topal CS; Sobay R; Alkurt G; Zemheri IE
    Pathol Res Pract; 2021 Jan; 217():153308. PubMed ID: 33341088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic and Predictive Value of O
    Zhang J; Zhu Y; Wang Y; Fu Q; Xie H; Liu Z; Fu H; Cao Y; Xu J; Dai B
    Ann Surg Oncol; 2018 Jan; 25(1):342-348. PubMed ID: 29116491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Soria F; Moschini M; Abufaraj M; Wirth GJ; Foerster B; Gust KM; Özsoy M; Briganti A; Gontero P; Mathieu R; Rouprêt M; Karakiewicz PI; Shariat SF
    Urol Oncol; 2017 Mar; 35(3):113.e9-113.e14. PubMed ID: 27908681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
    Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.
    Terlević R; Ulamec M; Štimac G; Murgić J; Krušlin B
    Biomol Biomed; 2023 Nov; 23(6):968-975. PubMed ID: 37389960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
    Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
    World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
    Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
    [TBL] [Abstract][Full Text] [Related]  

  • 55. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
    Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
    Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
    Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
    Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
    [No Abstract]   [Full Text] [Related]  

  • 58. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
    Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
    Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
    Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative Plasma Fibrinogen and D-dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer.
    Li X; Shu K; Zhou J; Yu Q; Cui S; Liu J; Zhou R; Ding D
    Clin Genitourin Cancer; 2020 Feb; 18(1):11-19.e1. PubMed ID: 31787543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.